Helen S. Te

Helen S. Te

Auto-generated profile, based on publicly available information

Helen S. Te

Center for Liver Diseases, Department of Medicine, University of Chicago Medicine, Chicago, Illinois, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2025 in Liver Transplantation
Verified
Journal Article
Closed access
HTHelen S. Te
Helen S. Te
VAVatche G. Agopian
Vatche G. Agopian
ADAnthony J. Demetris
Anthony J. Demetris
PKPaul Kwo
Paul Kwo
BMBrendan M. McGuire
Brendan M. McGuire
TSThomas D Schiano
Thomas D Schiano
Background and Aim: Advances in immunosuppression and surgical techniques in liver transplantation (LT) have significantly improved patient outcomes, but donor utilization and access to LT remain a challenge. The past decade has seen significant strides in donor pool expansion with acceptable clinical outcomes, while improved patient selection and advances in the management of chronic liver disease and post-LT complications have promoted better allograft health. This document aims to provide an evidence-based guideline on the management of graft complications, immunosuppression, graft rejection and recurrent disease in adult LT recipients. Methods: A multidisciplinary writing group of experts (transplant hepatologists, surgeons, pathologist, and psychiatrist) was tasked to formulate clinical questions (in PICO format) that arise during routine management of adult LT recipients. The writing group reviewed the literature, generated guideline recommendations and rated the level of evidence for each recommendation based on the Oxford Center for Evidence-Based Medicine. The group categorized the strength of recommendations based on the level of evidence, risk -benefit ratio, and patient preferences. Conclusion: While robust clinical trial data provide strong guidance on some aspects of graft management in LT such as machine perfusion and immunosuppression efficacy and safety, a significant component of graft management is derived from retrospective cohort data, extrapolation of data from other solid organ transplants, or expert opinion, including the treatment of antibody-mediated rejection. Finally, further investigation is needed to truly optimize the management of the liver allograft, including the prevention of recurrent alcohol-associated, metabolic dysfunction-associated steatotic and immune-mediated liver diseases.

8 May 2024 in American Journal of Transplantation
Verified
Journal Article
Open access
NNNewsha Nikzad
Newsha Nikzad
AFAndrew R. Fisher
Andrew R. Fisher
APAnjana Pillai
Anjana Pillai
LTLaura E. Targownik
Laura E. Targownik
HTHelen S. Te
Helen S. Te
SPSonali Paul
Sonali Paul
Liver transplantation is lifesaving for patients with end stage liver disease. Similar to the role of transplantation for patients with end stage liver disease, gender affirming hormone therapy (GAHT) can be lifesaving for transgender and gender diverse (TGGD) patients who experience gender dysphoria. However, management of such hormone therapy during the perioperative period is unknown and without clear guidelines. Profound strides can be made in improving care for TGGD patients through gender affirming care and appropriate management of GAHT in liver transplantation. In this article, we call for the transplant community to acknowledge the integral role of GAHT in the care of TGGD liver transplant candidates and recipients. We review the current literature and describe how the transplant community is ethically obligated to address this healthcare gap. We suggest tangible steps that clinicians may take to improve health outcomes for this minoritized patient population.

27 November 2024 in Transplant Infectious Disease
Verified
Journal Article
Closed access
DLDong Heun Lee
Dong Heun Lee
MAMaheen Z. Abidi
Maheen Z. Abidi
CFCynthia Fisher
Cynthia Fisher
AHAnna L. Hughart
Anna L. Hughart
MTMitsuru Toda
Mitsuru Toda
LDLara Danziger‐Isakov
Lara Danziger‐Isakov

30 June 2026 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
QYQian Yu
Qian Yu
PTPatrick Tran
Patrick Tran
TSTanner Storozuk
Tanner Storozuk
JSJoseph Steiner
Joseph Steiner
EUEthan Ungchusri
Ethan Ungchusri
THThuong Van Ha
Thuong Van Ha

16 June 2024 in Transplant Infectious Disease
Verified
Journal Article
Open access
HTHelen S. Te
Helen S. Te
DLDong Heun Lee
Dong Heun Lee
AWAnn E. Woolley
Ann E. Woolley
MAMaheen Z. Abidi
Maheen Z. Abidi
CFCynthia Fisher
Cynthia Fisher
LDLara Danziger‐Isakov
Lara Danziger‐Isakov
Background: Better access to direct‐acting antiviral (DAA) therapy has broadened the utilization of hepatitis C virus (HCV) nucleic acid testing (NAT) positive organs with excellent outcomes. However, DAA therapy has been associated with hepatitis B virus (HBV) reactivation.Aim: To determine the risk of HBV transmission or reactivation with utilization of HBV core antibody positive (HBcAb+) and HCV NAT positive (HCV+) organs, which presumably required DAA therapy.Methods: The number of HBcAb+ donors with delineated HCV NAT status was obtained from the Organ Procurement and Transplantation Network (OPTN) database. The number of unexpected HBV infections from transplanted organs adjudicated as “proven” or “probable” transmission was obtained from the OPTN Ad Hoc Disease Transmission Advisory Committee database. A chart review of the donors of “proven” or “probable” cases was conducted.Results: From January 1, 2016, to December 31, 2021, 7735 organs were procured from 3767 HBcAb+ donors and transplanted into 7469 recipients; 545 (14.5%) donors were also HCV+. HBV transmission or reactivation occurred in seven recipients. The rate is not significantly different between recipients of HCV+ (0.18%, 2/1115) and the HCV NAT negative (HCV‐) organs (0.08%, 5/6354) (p = 0.28) or between recipients of HCV+ and HCV‐ livers as well as non‐liver organs. HBV transmission or reactivation occurred within a median of 319 (range, 41–1117) days post‐transplant in the setting of missing, inadequate, or truncated prophylaxis.Conclusion: HBV reactivation associated with DAA therapy for HBcAb+ HCV+ organs is less frequent than reported in the non‐transplant population, possibly due to the common use of HBV prophylaxis in the at‐risk transplant population. image

28 March 2024 in ACG Case Reports Journal
Verified
Journal Article
Open access
JDJacob V. DiBattista
Jacob V. DiBattista
MOMatthew A. Odenwald
Matthew A. Odenwald
HTHelen Te
Helen Te
Se of chylous ascites in a patient with decompensated cirrhosis that was successfully managed with octreotide before liver transplantation....